A patient is taking Belsomra (suvorexant) 15 mg, clonidine hydrochloride extended‑release 0.1 mg four tablets at night, Klonopin (clonazepam) 1 mg at night, and Ativan (lorazepam) 2 mg (1–2 tablets) daily, yet continues to have insomnia and severe anxiety and wants Xanax (alprazolam) or Valium (diazepam) instead of lorazepam; how should their sleep and anxiety be managed?

Management of Refractory Insomnia and Anxiety in a Patient on Multiple CNS Depressants

Critical Assessment: This Polypharmacy Regimen is Dangerous and Ineffective

This patient is on an extremely hazardous combination of CNS depressants that violates evidence-based guidelines, and adding Xanax or Valium would further increase serious risks including respiratory depression, cognitive impairment, falls, and death—the priority must be systematic deprescribing and transition to safer alternatives, not adding more benzodiazepines. 1, 2, 3

Immediate Safety Concerns

Current Medication Burden Analysis

This patient is taking:

• Three concurrent benzodiazepines/benzodiazepine-like agents: Clonazepam 1mg, lorazepam 2-4mg, and clonidine ER 0.4mg (400 mcg—a dangerously high dose) 3
• One orexin antagonist: Belsomra 15mg 3
• Total daily benzodiazepine equivalents: Approximately 3-5mg of lorazepam equivalent, which is excessive 1, 2

The FDA explicitly warns that combining Belsomra with CNS depressants requires dosage reduction due to additive effects, yet this patient is on maximum or near-maximum doses of multiple agents simultaneously. 3

Why Adding Alprazolam or Diazepam is Contraindicated

• No evidence supports switching between benzodiazepines for treatment-resistant insomnia—if lorazepam and clonazepam are ineffective, alprazolam or diazepam will not work better 1, 2
• Alprazolam has the highest abuse potential and shortest half-life, leading to interdose rebound anxiety and worse outcomes 4
• Observational studies demonstrate that hypnotic use is associated with increased risk for dementia, fractures, and major injury—adding another benzodiazepine compounds these risks 1

Evidence-Based Management Strategy

Step 1: Recognize Treatment Failure and Underlying Issues

When insomnia persists despite multiple medications, the problem is typically:

• Tolerance to benzodiazepines (likely after chronic use) 1, 4
• Paradoxical hyperarousal from excessive CNS depressant load 5
• Untreated comorbid conditions (sleep apnea, restless legs, psychiatric disorders) 2, 5
• Lack of behavioral interventions 2

Step 2: Implement Cognitive Behavioral Therapy for Insomnia (CBT-I) FIRST

The American College of Physicians strongly recommends CBT-I as first-line treatment for chronic insomnia in all adults, before or concurrent with pharmacotherapy. 2

• CBT-I should be initiated immediately, either through in-person therapy, digital platforms (Somryst®), or telephone-based modules 2, 6
• CBT-I addresses the hyperarousal and maladaptive sleep behaviors that medications cannot fix 2
• This is non-negotiable—continuing to add medications without behavioral therapy perpetuates treatment failure 2

Step 3: Systematic Deprescribing Protocol

Begin tapering the most problematic agents while optimizing safer alternatives:

Phase 1: Discontinue Lorazepam (Ativan)

• Lorazepam should be tapered first because the patient is already on clonazepam (longer half-life, easier to manage) 4
• Reduce lorazepam by 0.5mg every 1-2 weeks to avoid withdrawal 4
• The patient's request to switch to another benzodiazepine reflects tolerance/dependence—address this directly with education about cross-tolerance 1, 4

Phase 2: Reduce Clonidine to Safe Dosing

• 0.4mg (four 0.1mg tablets) of clonidine ER is excessive and likely contributing to rebound hypertension/anxiety during the day
• Taper to 0.1-0.2mg maximum over 2-4 weeks 5

Phase 3: Optimize Belsomra or Consider Alternative Orexin Antagonist

• Belsomra 15mg is appropriate, but may be ineffective due to drug interactions with benzodiazepines 3, 7
• Once benzodiazepines are reduced, Belsomra efficacy may improve 7
• Consider switching to daridorexant (newer DORA with 8-hour half-life and 12-month efficacy data) if Belsomra remains ineffective after deprescribing 5, 6
• Suvorexant can worsen depression and cause suicidal ideation—monitor closely 3, 8

Phase 4: Gradual Clonazepam Taper

• After lorazepam is discontinued and patient is stable on CBT-I, begin slow clonazepam taper (0.25mg every 2-4 weeks) 4
• Goal is complete benzodiazepine discontinuation given lack of efficacy and significant harm profile 1, 2

Step 4: Address Anxiety with Non-Benzodiazepine Agents

For persistent anxiety during deprescribing:

• SSRIs or SNRIs (escitalopram, sertraline, venlafaxine) are first-line for generalized anxiety disorder 5
• Pregabalin or gabapentin can help with both anxiety and insomnia during benzodiazepine taper 4
• Buspirone for anxiety (though takes 2-4 weeks for effect) 5

Step 5: Alternative Sleep Medications if Needed

If insomnia persists after CBT-I and deprescribing:

• Low-dose doxepin (3-6mg) for sleep maintenance insomnia—FDA-approved, minimal next-day effects 4, 5
• Ramelteon 8mg for sleep onset insomnia 4, 5
• Lemborexant or daridorexant (newer DORAs with better evidence than suvorexant) 6, 5

Research demonstrates that switching from benzodiazepines to suvorexant or eszopiclone improves insomnia severity in treatment-resistant cases (ISI score improvement of -4.3 for suvorexant at 4 weeks, p=0.04). 7

Critical Warnings and Pitfalls

Drug Interaction Alert

• Belsomra is metabolized by CYP3A4—any CYP3A4 inhibitors (diltiazem, macrolides, azole antifungals, grapefruit juice) will increase suvorexant levels and cause severe next-day somnolence 9
• Dose should be reduced to 5mg if moderate CYP3A4 inhibitors are present 3

Monitoring During Deprescribing

• Benzodiazepine withdrawal can be life-threatening—taper slowly and monitor for seizures, severe anxiety, autonomic instability 4
• Suvorexant can cause worsening depression and suicidal ideation—one case report documented acute suicidal thoughts within hours of dose increase 8
• Falls and cognitive impairment risk remains elevated until all benzodiazepines are discontinued 1, 3

Patient Education

• Explain that cross-tolerance between benzodiazepines means switching will not improve efficacy 4
• Discuss that current regimen is causing harm (cognitive impairment, fall risk, dementia risk) even if patient feels dependent on medications 1
• Set realistic expectations: sleep may temporarily worsen during taper but will improve with CBT-I and time 2

What NOT to Do

• Do not prescribe alprazolam or diazepam—this adds risk without benefit 1, 4
• Do not continue current polypharmacy indefinitely—this guarantees treatment failure and serious adverse events 1, 2
• Do not increase Belsomra dose above 20mg—higher doses increase somnolence without proportional efficacy gain 3
• Do not use quetiapine, trazodone, or other off-label sedating agents without first attempting evidence-based approaches 4